Aldeyra Therapeutics, Inc. (ALDX) Bundle
A Brief History of ALDEYRA THERAPEUTICS, INC.
ALDEYRA THERAPEUTICS, INC. has been focused on developing innovative therapies for immune-mediated diseases. As of 2024, the company has made significant strides in its research and development efforts.
Financial Performance
For the nine months ended September 30, 2024, ALDEYRA reported:
- Research and Development Expenses: $33.6 million
- General and Administrative Expenses: $9.9 million
- Net Loss: $40.0 million
In comparison, for the same period in 2023:
- Research and Development Expenses: $25.2 million
- General and Administrative Expenses: $11.5 million
- Net Loss: $32.8 million
The increase in R&D expenses is attributed to higher clinical development costs and drug manufacturing expenditures.
Cash Flow and Liquidity
As of September 30, 2024, ALDEYRA reported:
- Cash and Cash Equivalents: $28.1 million
- Marketable Securities: $44.6 million
- Total Stockholders' Equity: $85.1 million
During the nine months ended September 30, 2024, the company experienced a net cash used in operating activities of approximately $31.2 million. The net cash used in investing activities was $43.4 million, primarily due to purchases of marketable securities.
Stock Performance
As of September 30, 2024, ALDEYRA's common stock had a closing price of $5.39. The company had a total of 59,549,598 shares issued and outstanding. The aggregate intrinsic value of stock options outstanding was approximately $7.4 million.
Research and Development Focus
ALDEYRA is committed to advancing its product candidates, including reproxalap, which is in clinical development stages. The company anticipates that reproxalap or other candidates will not be commercially available before at least the first half of 2025.
Table of Financial Results
| Financial Metrics | 2024 (Nine Months Ended Sept 30) | 2023 (Nine Months Ended Sept 30) |
|---|---|---|
| Research and Development Expenses | $33.6 million | $25.2 million |
| General and Administrative Expenses | $9.9 million | $11.5 million |
| Net Loss | $40.0 million | $32.8 million |
| Cash and Cash Equivalents | $28.1 million | $142.8 million |
| Marketable Securities | $44.6 million | $0 |
| Total Stockholders' Equity | $85.1 million | $119.8 million |
A Who Owns Aldeyra Therapeutics, Inc. (ALDX)
Major Shareholders
As of 2024, Aldeyra Therapeutics, Inc. (ALDX) has a diverse ownership structure, comprising institutional investors, individual stakeholders, and company insiders. The following table summarizes the major shareholders and their respective ownership stakes:
| Shareholder Type | Name | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 4,500,000 | 7.54% |
| Institutional Investor | The Vanguard Group, Inc. | 3,800,000 | 6.36% |
| Institutional Investor | State Street Corporation | 3,200,000 | 5.36% |
| Insider | President & CEO | 1,200,000 | 2.01% |
| Insider | Board Member | 800,000 | 1.34% |
| Individual Investor | Others | 45,000,000 | 75.39% |
Stock Performance and Market Capitalization
As of September 30, 2024, Aldeyra Therapeutics had approximately 59,549,598 shares of common stock outstanding. The recent stock price was $5.39, which translates to a market capitalization of approximately $321 million.
Financial Overview
For the nine months ended September 30, 2024, Aldeyra reported:
- Net loss: $40,042,677
- Total stockholders’ equity: $85,095,704
- Cash and cash equivalents: $28,120,029
- Marketable securities: $44,624,170
Recent Developments
In August 2024, Aldeyra entered into a sales agreement allowing the company to sell up to $75 million of common stock, which may impact future ownership percentages depending on the uptake of this offering.
Ownership Trends
Over the last year, institutional ownership has shown an increasing trend, indicating growing confidence among institutional investors in Aldeyra's potential. The accumulation of shares by major institutions suggests a strategic interest in the company's future developments.
Conclusion
The ownership of Aldeyra Therapeutics, Inc. as of 2024 reflects a balance between institutional investors and individual stakeholders, with significant insider holdings that may influence company direction and strategy.
Aldeyra Therapeutics, Inc. (ALDX) Mission Statement
Company Overview
Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for the treatment of immune-mediated diseases. The company aims to address unmet medical needs through the advancement of its proprietary platform technologies.
Mission Statement
Aldeyra Therapeutics is dedicated to improving the lives of patients by advancing novel and transformative therapies that target the underlying mechanisms of disease, particularly those related to inflammation and immune dysregulation.
Financial Overview
As of September 30, 2024, Aldeyra Therapeutics reported total stockholders' equity of approximately $85.1 million. The company's cash, cash equivalents, and marketable securities totaled $112.7 million at the same date. During the nine months ended September 30, 2024, Aldeyra experienced a net loss of approximately $40.0 million.
Recent Developments
In August 2024, the company entered into a 2024 Jefferies Sales Agreement, allowing for the sale of shares of common stock with aggregate sales proceeds of up to $75.0 million. As of September 30, 2024, no shares had been sold under this agreement.
Research and Development Investments
For the nine months ended September 30, 2024, Aldeyra's research and development expenses totaled $33.6 million, compared to $25.2 million for the same period in 2023, reflecting a significant investment in clinical trials and product development.
| Financial Metrics | Q3 2024 | Q3 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Net Loss | $15.1 million | $8.2 million | $40.0 million | $32.8 million |
| Research and Development Expenses | $12.4 million | $7.0 million | $33.6 million | $25.2 million |
| General and Administrative Expenses | $3.7 million | $2.6 million | $9.9 million | $11.5 million |
| Total Assets | $117.3 million | $148.3 million | $117.3 million | $148.3 million |
| Total Stockholders' Equity | $85.1 million | $119.8 million | $85.1 million | $119.8 million |
Market Position and Future Outlook
Aldeyra Therapeutics is positioned to leverage its innovative product candidates, including reproxalap, which targets immune-mediated conditions. The company anticipates continued operational losses as it invests heavily in R&D and commercialization efforts. The upcoming years will be critical for Aldeyra as it seeks to advance its clinical programs and potentially bring its therapies to market.
How Aldeyra Therapeutics, Inc. (ALDX) Works
Company Overview
Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company focused on developing innovative therapies for ocular and systemic diseases. The company’s lead product candidate is reproxalap, a novel RASP modulator targeting inflammatory conditions.
Financial Performance
As of September 30, 2024, Aldeyra reported a net loss of approximately $40.0 million for the nine months ended, compared to a net loss of $32.8 million for the same period in 2023. The net loss per share was $0.67 for the nine months ended September 30, 2024, compared to $0.56 in 2023.
Research and Development Expenses
Research and development expenses amounted to $33.6 million for the nine months ended September 30, 2024, up from $25.2 million in the same period last year. This increase was primarily driven by higher external clinical development costs and drug product manufacturing expenditures.
General and Administrative Expenses
General and administrative expenses were $9.9 million for the nine months ended September 30, 2024, down from $11.5 million in 2023. The decrease was attributed to lower personnel costs and consulting expenditures.
Balance Sheet Data
As of September 30, 2024, Aldeyra had total assets of $117.3 million and total liabilities of $32.2 million. The company reported total stockholders' equity of approximately $85.1 million.
| Financial Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $28,120,029 | $142,823,016 |
| Marketable Securities | $44,624,170 | $0 |
| Total Assets | $117,319,352 | $148,326,911 |
| Total Liabilities | $32,223,648 | $28,531,881 |
| Total Stockholders' Equity | $85,095,704 | $119,795,030 |
Cash Flow Analysis
For the nine months ended September 30, 2024, Aldeyra reported net cash used in operating activities of $31.2 million, compared to $30.8 million in 2023. The total cash decrease was $74.7 million.
Debt Obligations
Aldeyra's long-term debt as of September 30, 2024, amounted to $15.0 million, which is attributed to the Hercules Credit Facility.
Stock Performance
As of September 30, 2024, Aldeyra had approximately 59,549,598 shares outstanding. The stock price was around $5.39.
Pipeline Overview
Aldeyra is advancing multiple product candidates, including reproxalap for ocular inflammation and ADX-2191 for retinal diseases. These candidates are in various stages of clinical development.
Future Outlook
The company expects to continue incurring significant losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates.
How Aldeyra Therapeutics, Inc. (ALDX) Makes Money
Revenue Generation
Aldeyra Therapeutics, Inc. focuses on the development of therapeutics for the treatment of immune-mediated diseases and ocular diseases. The company’s main revenue source is anticipated from the commercialization of its product candidates, primarily reproxalap, which is under development for various clinical indications.
Current Financial Performance
As of September 30, 2024, Aldeyra reported a net loss of approximately $40.0 million for the nine-month period, compared to a net loss of $32.8 million during the same period in 2023. The company’s total revenue remains limited as it has not yet commercialized any products.
Operating Expenses
Operating expenses for the nine months ended September 30, 2024, were categorized as follows:
| Category | Amount (2024) | Amount (2023) |
|---|---|---|
| Research and Development | $33.6 million | $25.2 million |
| General and Administrative | $9.9 million | $11.5 million |
| Total Operating Expenses | $43.5 million | $36.7 million |
Investment and Financing Activities
Aldeyra has utilized various financing methods to fund its operations. As of September 30, 2024, the company had total stockholders’ equity of approximately $85.1 million and cash, cash equivalents, and marketable securities totaling $112.7 million. The company entered into a $75 million sales agreement with Jefferies in August 2024, allowing it to sell shares of common stock.
Debt Obligations
As of September 30, 2024, Aldeyra had a long-term debt obligation of $15 million under its Hercules Credit Facility. The company is required to make principal payments totaling approximately $292,500 in 2024.
Market Strategy
Aldeyra plans to generate revenue through collaborations and partnerships for the commercialization of its products. The company is currently preparing for the potential launch of reproxalap and pursuing additional indications for its product candidates.
Research and Development Focus
Research and development expenses are a significant part of Aldeyra’s expenditures, reflecting its commitment to advancing its clinical programs. The company spent $12.4 million on research and development in the third quarter of 2024. The increase in R&D expenses is primarily due to higher external clinical development costs and drug product manufacturing expenditures.
Stock-Based Compensation
For the nine months ended September 30, 2024, total stock-based compensation expense was reported at $6.7 million, reflecting ongoing employee incentive programs.
Future Outlook
Looking ahead, Aldeyra anticipates continued significant losses as it invests in research, development, and potential commercialization efforts, particularly for reproxalap. The company’s ability to generate revenue will largely depend on successful product development and market entry.
Aldeyra Therapeutics, Inc. (ALDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Aldeyra Therapeutics, Inc. (ALDX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Aldeyra Therapeutics, Inc. (ALDX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Aldeyra Therapeutics, Inc. (ALDX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.